(3-(1H-benzo[d]imidazol-2-yl)-1H-indazol-5-yl)(4-methyl-1,4-diazepan-1-yl)methanone | 1264922-92-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: (3-(1H-benzo[d]imidazol-2-yl)-1H-indazol-5-yl)(4-methyl-1,4-diazepan-1-yl)methanone
• 英文别名: [3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-(4-methyl-1,4-diazepan-1-yl)methanone
• CAS: 1264922-92-0
• 化学式: C₂₁H₂₂N₆O
• 分子量: 374.445
• InChiKey: ATVMPIRBISHOEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  80.9
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF
  申请人：Hood John

  公开号：US20110034441A1

  公开（公告）日：2011-02-10

  Described herein are methods of treating a disorder or disease in which aberrant Wnt signaling is implicated, with a variety of compounds, including Wnt inhibitor compounds. More particularly, it concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components.

  本文描述了一种治疗与异常Wnt信号传导有关的疾病或紊乱的方法，使用各种化合物，包括Wnt抑制剂化合物。更具体地，涉及使用吲唑化合物或其类似物治疗由Wnt途径信号激活所特征的疾病（如癌症、异常细胞增殖、血管生成、阿尔茨海默病和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt信号传导组分突变引起的遗传疾病。